Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma

Neuroblastoma Clinical Trial

— EQUI-HIPPO  

Official title:

Pilot Study Evaluating Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma and Describing the Evolution of Their Physical and Psychological Characteristics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05755295
• Other study ID #: RC31/22/0218
• Status: Recruiting
• Phase: N/A
• Start date: April 3, 2023
• Est. completion date: March 1, 2026

Study information

• Verified date: July 2023
• Source: University Hospital, Toulouse
• Contact: Anne-Isabelle BERTOZZI, MD
• Phone: 05 34 55 86 83
• Email: bertozzi.ai[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care.

The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: March 1, 2026
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 26 Years

Eligibility

Inclusion Criteria:

• complete remission of medulloblastoma and after 5 years of the end of treatment

• living within 30 km away the riding center and/or less than 1 hour of transport

• informed consent

Exclusion Criteria:

• Landsky score below 50% for minors until 16 years old and Karnofsky score below 50% for patients over 16 years

• major under juridical protection

Related Conditions & MeSH terms

• Medulloblastoma
• Neuroblastoma

Intervention

Other:
• horse therapy
equitherapy and hippotherapy once a week during 16 weeks

Locations

Country	Name	City	State
France	CHU de Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of sessions performed	number of sessions equitherapy and hippotherapy performed	16 weeks